Products for Research Use Only

Olomoucine

CAT: 0804-HY-W011428-01Size: 1 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-W011428-01Size:1 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Olomoucine is an ATP competitive inhibitor of CDKs. Olomoucine is a purine derivative and inhibits CDC2/cyclin B, Cdk2/cyclin A, Cdk2/cyclin E (both IC50=7 μM), CDK/p35 kinase (IC50=3 μM) and ERK1/p44 MAP kinase (IC50=25 μM)[2]. Olomoucine regulates cell cycle and shows anti-melanin tumor activity[3][4].
CAS Number
101622-51-9
UNSPSC
12352005
Hazard Statement
H315, H319, H335
Target
CDK
Type
Reference compound
Related Pathways
Cell Cycle/DNA Damage
Applications
Cancer-Kinase/protease
Field of Research
Others; Cancer
Assay Protocol
https://www.medchemexpress.com/olomoucine.html
Purity
99.88
Solubility
DMSO : 66.67 mg/mL (ultrasonic)
Smiles
CN1C=NC2=C(NCC3=CC=CC=C3)N=C(NCCO)N=C12
Molecular Formula
C15H18N6O
Molecular Weight
298.34
Precautions
H315, H319, H335
References & Citations
[1]Vesely, J., Havlicek, J., Strnad, M., et al. Inhibition of cyclin-dependent kinases by purine analogues. European Journal of Biochemistry 224, 771-786 (1994) .|[2]Abraham, R.T., Acquarone, M., Andersen, A., et al. Cellular effects of olomoucine, an inhibitor of cyclin-dependent kinases. Biology of the Cell 83 (2), 105-120 (1995) .|[3]Hajdúch M, et al. Induction of apoptosis and regression of spontaneous dog melanoma following in vivo application of synthetic cyclin-dependent kinase inhibitor olomoucine. Anticancer Drugs. 1997 Nov. 8 (10) :1007-13.|[4]Raynaud FI, et al. Cassette dosing pharmacokinetics of a library of 2,6,9-trisubstituted purine cyclin-dependent kinase 2 inhibitors prepared by parallel synthesis. Mol Cancer Ther. 2004 Mar. 3 (3) :353-62.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
CDK2; CDK5